Keywords: Biogen Idec, Tysabri, Sales, Multiple sclerosis, Fampridine, Research, Trillium, Licensing

Biogen Idec’s Tysabri surpasses $1 billion in 2009 sales; fampridine filed in EU, Canada; development deal with Trillium

Article | 13 January 2010

Print This

In a presentation to investors at the JP Morgan Healthcare Conference in San Francisco, USA, Biogen Idec’s outgoing chief ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in